Science News
from research organizations

Unraveling How A Drug Helps Patients With Multiple Sclerosis

Date:
April 1, 2008
Source:
Journal of Clinical Investigation
Summary:
Although the drug IFN-beta is commonly used to treat individuals with the relapsing-remitting form of multiple sclerosis, little is known about the mechanism(s) by which it acts. However, a mechanistic pathway by which IFN-beta reduces disease in a mouse model of MS known as EAE has now been reported and is mediated, at least in part, by the soluble factor IL-27.
Share:
FULL STORY

Although the drug IFN-beta is commonly used to treat individuals with the relapsing-remitting form of multiple sclerosis (MS), little is known about the mechanism(s) by which it acts. However, Genhong Cheng and colleagues, at the University of California at Los Angeles, have now reported a mechanistic pathway by which it reduces disease in a mouse model of MS known as EAE.

In addition to being a drug, IFN-beta is produced naturally by the body during certain immune responses. In the study, mice lacking a component of the molecule to which IFN-beta binds to mediate its effects were found to develop more severe EAE than mice expressing this protein.

This was associated with increased numbers of immune cells known as Th17 cells in the central nervous system of the mice, the part of the body affected in individuals with MS. Further experiments showed that disease could be alleviated in these mice by administration of a soluble molecule known as IL-27, leading the authors to suggest that in individuals with MS, the beneficial effects of IFN-beta are likely to be mediated, at least in part, through its ability to induce the secretion of IL-27.

Journal reference: The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. Journal of Clinical Investigation. April 2, 2008.


Story Source:

Materials provided by Journal of Clinical Investigation. Note: Content may be edited for style and length.


Cite This Page:

Journal of Clinical Investigation. "Unraveling How A Drug Helps Patients With Multiple Sclerosis." ScienceDaily. ScienceDaily, 1 April 2008. <www.sciencedaily.com/releases/2008/04/080401184921.htm>.
Journal of Clinical Investigation. (2008, April 1). Unraveling How A Drug Helps Patients With Multiple Sclerosis. ScienceDaily. Retrieved September 26, 2016 from www.sciencedaily.com/releases/2008/04/080401184921.htm
Journal of Clinical Investigation. "Unraveling How A Drug Helps Patients With Multiple Sclerosis." ScienceDaily. www.sciencedaily.com/releases/2008/04/080401184921.htm (accessed September 26, 2016).